Another 17,500 buy @ $11.04. Looks like slow accumulation has started. Now all we need is some upgrades after the conference.

We just got a 12,500 share trade at $11 so things are picking up.

I don't think there was any block buying. I wasn't watching the open since I'm not trading RPRX, but the trading history log on business week does not show any big buys.

We need a big buyer to get rid of these flippers.

11,200 share buy at $10.93. Showing some nice strength today.

Y3maxx, looks like the 25% chance of going higher won this time. I noticed you haven't been posting your $8 price predictions.

WHY SHOULD I INVEST IN ANX:

1)If I gave you the worse case scenario for "Co-factor" in the clinical trials then it should still gain FDA approval and be a $250 million drug minimum.
Whats the worse case scenario? Co-factor does not show a statistical advantage over Leucovorin for safety or efficacy.

Then why would "Co-factor" gain FDA approval. Because Leucovorin takes two hours to infuse and Co-factor can be given as a bolus. Which one will you and doctors choose? I'll take the bolus. It saves money and time.

2)Question two: Why can't I just give a big dose of Leucovorin in order to achieve the same cellular level of MTHF as co-factor.

Negative feedback mechanisms prevent Leucovorin from achieving the optimum level of MTHF. CoFactor must be present in concentrations exceeding 10uM in order to effect total inhibition of the enzyme TS. However, standard doses of leucovorin do not provide serum CoFactor in this 10uM concentration range. For example, intravenous leucovorin doses of 10mg/m2 to 500mg/m2 result in serum CoFactor concentrations of only 0.047uMto 2.3uM. A 500mg/m2intravenous dose of leucovorin is the maximum used by most bolus dosing regimens in chemotherapy. Therefore, the available pharmacodynamic data suggest that standard 5-FU/leucovorin-based dosing strategies lead to suboptimal plasma levels of CoFactor, resulting in incomplete inhibition of thymidylate synthase and poor tumor control.

Intravenous CoFactor dosing regimens provide clinically relevant
plasma levels of the drug. In one study, average plasma levels of CoFactor following 100mg and 200mg doses were 18.6uM and 46.3uM.

This is the key why Co-factor has improved efficacy over Leucovorin.

So ANX has a drug with No safety concerns, improved administration, clinical trials have shown less adverse events including anemia, improved efficacy, and a large market.

As soon as we get rid of the short or get positive Phase IIb results then its headed to $5.00.

For those new to ANX. The most important catalyst near term is the Phase IIb results for "Co-factor". Top-line results should be reported in the third qtr., but June is a possibility.

The Phase IIb is for CRC. Co-factor is also in Phase III, 1200 pt. trial for CRC and a Phase II trial for Breast CA.

Co-factor has potential sales of over 500 million. PFE & Roche have been mentioned as possible partners by ThinkEquity after Phase IIb results.

Amazing story of a successful treatment with Tovaxin.

http://www.ihavems.com/

quantumdot, thanks for mentioning the stock yesterday. I bought @ $4.50 yesterday and sold today @ $7.07. It may go higher, but I couldn't resist taking the easy money.

Yea, that may have been one of my best buys in awhile ($4.50). I'm up 4 thousand in a few hours. Just hope no one sells 100 shares or I'll probably lose all the gains. Crazy spreads on the bid/ask with such a low float.

OPXA- I took a position after looking over the PR and briefly reviewing the info on their website. I like the story and DNDN's news may bring the company some added attention.

Bio-tech investors can't decide if todays news is bad or good. I guess we need an upgrade so people will understand that this was a positive announcement.

I listened to the presentation and I still think management is hyping the stock. Of course my opinion may be influenced since anesthesia is my profession.

How do you know that no new funds or big boys have taken a position? Someone has been accumulating every cheap share that comes on the market for the last few weeks. Better start buying or your going to be left on the sidelines.

This is not the yahoo board where all the posters are a bunch of overextended amateurs on margin. The MM or shorts have no impact on my investing. As far as my posts, just venting my frustration on the price action. I've still got plenty of bullets.

The stock has already revisited the last low when you consider that RPRX has $3.50 of cash per share on hand which it didn't a year ago. We know Y3maxx has an agenda and it shouldn't be allowed on this board. Dr. Bill should erase his posts and give him a warning that he will be kicked off the board.

Y3maxx, Your true colors are showing. I guess you have to bash here since the yahoo message board does not work.

SIGA- caught a nice break. ST-246 has not even completed safety trials and was used to save a child.

"Experimental drugs bring Ind. boy back from brink of death

March 18, 2007
BY DAVE NEWBART Staff Reporter
A 2-year-old boy stricken with a rare infection from the smallpox vaccine is improving but remained in critical condition Saturday at the Comer Children's Hospital at the University of Chicago.

The boy was infected by his father, a U.S. soldier who was vaccinated in January in preparation for service in Iraq. But his deployment was delayed, and he returned home to Indiana late last month. His son, who suffers from skin lesions known as eczema, then became infected by vaccinia, a virus similar to smallpox and used in the vaccine against it.

The boy is the first person to suffer from the severe infection, known as eczema vaccinatum, since the U.S. military began inoculating troops in 2002. But his condition is so uncommon that U. of C. experts said they could not find reports of any cases in the United States since before 1972, when routine vaccinations for smallpox were halted.

Only seen in photos
"This is something that is new to us," said Kenneth Alexander, head of pediatric infectious disease at U. of C.

The boy, whose name was not released, was sent to U. of C. from a northwest Indiana hospital March 3 after he developed a severe rash. He didn't improve after treatment, and by March 7, a dermatologist noticed his lesions resembled those caused by smallpox -- something doctors had only seen in photos because the disease was eradicated.

Doctors contacted the federal Centers for Disease Control and Prevention, which agreed to fly in a treatment never used on a child, vaccinia immune globulin (VIG). The drug was hand-delivered by U.S. marshals.

The boy's condition continued to worsen, and last weekend, his lungs and kidneys began to fail. "He was near death," said Madelyn Kahana, chief of pediatric critical care medicine. Painful skin lesions covered most of his body.

'He is slowly improving'
The CDC then asked the Food and Drug Administration to grant emergency permission to try ST-246, an experimental drug being developed to fight smallpox. It had been effective in treating mice and monkeys infected with the virus, said U. of C. pediatrician John Marcinak, who is spearheading the boy's treatment. But it had never been used on a sick person.

That, combined with VIG and another drug, seems to be working. Since he first got the drug March 11, "he is slowly improving," Marcinak said.

The boy's mother contracted a milder form of the vaccinia virus from the boy and has been quarantined in the boy's room but is recovering well, officials said".

Amazing that the CDC authorized SGA-246 to be given to a child. I wonder if any drug has been used to save a childs life that has not even completed Phase I safety studies?
Going to be a big week for SIGA. Probably in the national press all week.

Jav is a hyped stock. I saw the new price target by Punk, but I wonder what the revenue estimates are. Dylojet will never have a big market in the U.S. due to Toradol's acceptance and I wonder about the competition in the E.U.

Intranasal Ketamine - I can see alot of uses for the drug, but they have not started Phase III.

Repros - I need to stay away from my computer or I may buy more.

Unbelievable, I'm getting crushed on this one. I feel like the secondary buyers @ $13.75.

I'm all in. Bought the last shares today @ $9.20

y3maxx, if I didn't know better I would think your trying to cast doubt in investors minds. RPRX has bottomed. Cheap shares are being accumulated.

"When was this report written?" Mar/08/07 Summary of Punk-Zeigel from briefing.com.and $3 price target.

Dew, have you ever analyzed the interim results reported in clinical trials to the final analysis? Do you believe that interim and final results are closely correlated in most trials or is there a large degree of statistical difference?

I know that its hard to compare studies due to the variations in trial design, but in your experience how do you weigh interim results.

AIS - Briefing.com gave a summary of Punk's analysis. They believe AIS represents an under-recognized, under-valued, and mis-understood opportunity. They anticipate several important catalysts driving AIS valuation during the next 12 months, including advancement of Anturol into pivotal clinical trials for incontinence, approval of first product under the TEVA deal, receipt of significant milestones relating to Elestrin; and increased revenues with decreased operating losses, indicating AIS is achieving a sustainable business.

I think the CEO stated that they would be cash flow positive this year during his last presentation.

rfj, I think Punk upgraded based on AIS's potential revenues from their TEVA agreements. They have three different agreements for their needle-free injection system, but the details are lacking.

Google - Teva & AIS.

I wonder what percentage of companies report final Phase II data in-line with interim results. There are so many trial designs that it makes comparisons difficult, but I can't believe our final analysis would have much variability from the interim results.

Enrollment in the Proellex Phase II trial was completed in the middle of December. Its a 12 week study so shouldn't we be getting results soon? I can't remember if management has given a timeline for the final results.

RPRX was trading in the same range a year ago with less money in the bank & less clinical data. I don't know what the market is waiting on. I guess they would rather buy $3 or $4 higher after the next PR.

"I've got some insight into a few other things Repros" Could you share this insight with the board. We're all taking a bath and could use some positive spin.

Looked like a sell to me. One of the hedges must be raising money. Hope he doesn't have more shares to unload.

"Anyone hear anything about a new drug" They may be talking about "ELI". They are developing a combination drug oxycodone hydrochloride and opioid antagonist, naltrexone hydrochloride, which blocks the euphoric effect of the opioid if the product is abused.

We'll be trading for cash value pretty soon. The sell-off has gotten stupid.

I skimmed the prospectus this weekend, but I didn't come across a lock-up period. I think some of our trading weakness resulted from the failure to place the over-allotment shares. Shorts realized that there was not any buying interest in the $13.75 range and shorted the stock.

I think the recent weakness will continue until we get updated clinical data. The markets not going to put alot of money in the more speculative investments/bio-techs and I don't anticipate any partnership or licensing agreements. Hopefully this is the bottom, but its going to depend on the overall market strength.

All bio-techs are on sale, RPRX is no different.

Why would they issue a PR? The company is not going announce that there was no over-allotment.

Just what we need, a basher on the board.

I need to watch the market a little before I buy anymore bio-techs. My buying spree last week has got me in some serious red figures. Looks like the smart investors liquidated all their positions and now their trying to push the market lower by shorting and predicting that the world is coming to an end. Of course its only a game to get the weak to sell.

Wizardd, Don't look now but we're up .94 in after hours. Of course its only 500 shares. Maybe Podolski bought them with the his 98K bonus. See todays 8-K.

My comment about not liking the stock was in reference to the financial pain today and not about the pipeline. I bought some more shares today since it has to be one of the most undervalued bio-techs.

I used to like this stock, but we get taken down hard with any selling due to the low volume. Dropped 8% on 100K shares and never recovered. I guess one of the little hedges that owns shares needed to raise cash.

Does anyone expect anything from the company before May?